Skip to main content
  • Clinical
      |Clinical
    • Acute Coronary Syndromes
    • Cardiac Surgery
    • Covid-19
    • Heart Failure
    • Heart Health
    • Heart Rhythm
    • Hypertension
    • Interventional Cardiology
    • Mitral Valve
    • Pharmaceutics
    • Structural Heart Disease
    • TAVR
    • Tricuspid Valve
    • Vascular & Endovascular
  • Management
      |Management
    • Chest Pain Guidelines
    • Compensation
    • Economics
    • Education & Training
    • Legal News
    • Patient Care
    • Policy & Regulations
    • Professional Associations
    • Quality
    • Revenue
    • Staffing
  • Technology
      |Technology
    • AI
    • Cardiac Imaging
    • Cath Lab
    • CT
    • CVIS
    • ECG
    • Echo
    • EP Lab
    • Informatics
    • MRI
    • Nuclear Cardiology
    • Remote Monitoring
  • Videos
  • Conferences
      |Conferences
    • ACC
    • AHA
    • ASE
    • ASNC
    • ESC
    • EuroPCR
    • HFSA
    • HRS
    • SCAI
    • SCCT
    • SIIM
    • SNMMI
    • STS
    • TCT
    • VIVA
  • Custom Content
      |Custom Content
    • Experience Stories
    • Webinars & Videos
  • Subscribe
  • Forty Under 40 Award
      |Forty Under 40 Award
    • Class of 2026
    • Class of 2025

Search form

Home

Early reactions to proposed TAVR changes | Cardiology still an AI leader | More than 11K bottles of blood pressure drug recalled

News You Need to Know Today
Early reactions to proposed TAVR changes | Cardiology still an AI leader | More than 11K bottles of blood pressure drug recalled
Thursday, June 18, 2026
Link to Twitter Link to Facebook Link to Linkedin Link to Vimeo

Today's News and Trends

Cardiologists and surgeons share early feedback after CMS proposed sweeping TAVR changes

Major TAVR policy changes appear to be on the way—should clinicians be excited or concerned? Leading U.S. medical societies are sharing their early reactions.

READ MORE >
Heart cardiologists doctors surgery
Share on Twitter Share on Facebook Share on Linkedin

Cardiologists and surgeons share early feedback after CMS proposed sweeping TAVR changes

Share on Twitter Share on Facebook Share on Linkedin
Heart cardiologists doctors surgery
Major TAVR policy changes appear to be on the way—should clinicians be excited or concerned? Leading U.S. medical societies are sharing their early reactions.
READ MORE >

Cardiology still one of the top specialties for FDA-cleared AI algorithms

Cardiology remains the No. 2 healthcare specialty for AI approvals, trailing only radiology. 

READ MORE >
The Boston Scientific BodyGuardian Remote Monitoring System uses AI to help detect and monitor cardiac arrhythmias in ambulatory patients.
Share on Twitter Share on Facebook Share on Linkedin

Cardiology still one of the top specialties for FDA-cleared AI algorithms

Share on Twitter Share on Facebook Share on Linkedin
The Boston Scientific BodyGuardian Remote Monitoring System uses AI to help detect and monitor cardiac arrhythmias in ambulatory patients.
Cardiology remains the No. 2 healthcare specialty for AI approvals, trailing only radiology. 
READ MORE >

More than 11K bottles of blood pressure drug recalled

Certain lots of a popular diuretic have been recalled due to concerns about the drug's effectiveness. 

READ MORE >
pills-384846_960_720.jpg
Share on Twitter Share on Facebook Share on Linkedin

More than 11K bottles of blood pressure drug recalled

Share on Twitter Share on Facebook Share on Linkedin
pills-384846_960_720.jpg
Certain lots of a popular diuretic have been recalled due to concerns about the drug's effectiveness. 
READ MORE >

Featured Articles

'Not sustainable': The real impact of RVU cuts in electrophysiology

Despite a substantial increase in demand for electrophysiologists, payments for their services have remained stagnant. 

READ MORE >
Joshua R. Silverstein, MD, FHRS, a cardiac electrophysiologist at Allegheny Health Network Cardiovascular Institute, explains the real-world impacts of Centers of Medicare and Medicaid Services (CMS) RVU cuts in electrophysiology.
Share on Twitter Share on Facebook Share on Linkedin

'Not sustainable': The real impact of RVU cuts in electrophysiology

Share on Twitter Share on Facebook Share on Linkedin
Joshua R. Silverstein, MD, FHRS, a cardiac electrophysiologist at Allegheny Health Network Cardiovascular Institute, explains the real-world impacts of Centers of Medicare and Medicaid Services (CMS) RVU cuts in electrophysiology.
Despite a substantial increase in demand for electrophysiologists, payments for their services have remained stagnant. 
READ MORE >

Family files $17M lawsuit after young girl’s heart valve allegedly implanted upside down

Days went by and the girl's doctors never figured out what was wrong. When she was transferred to a different hospital, however, the issue was quickly identified and corrected. 

READ MORE >
A gavel and a stethoscope
Share on Twitter Share on Facebook Share on Linkedin

Family files $17M lawsuit after young girl’s heart valve allegedly implanted upside down

Share on Twitter Share on Facebook Share on Linkedin
A gavel and a stethoscope
Days went by and the girl's doctors never figured out what was wrong. When she was transferred to a different hospital, however, the issue was quickly identified and corrected. 
READ MORE >

CMS proposes major TAVR changes, including Medicare coverage for asymptomatic patients

After months of consideration, CMS has proposed sweeping changes to its TAVR coverage policies. The agency is accepting public comments until July 15.

READ MORE >
2024 has been a banner year for structural heart treatments, especially those focused on the tricuspid valve. In February, for example, Edwards Lifesciences made history when its Evoque transcatheter tricuspid valve replacement (TTVR) system became the first device of its kind to gain U.S. Food and Drug Administration (FDA) approval for treating tricuspid regurgitation (TR). Two months later, Abbott’s TriClip transcatheter edge-to-edge repair (TEER) system also gained FDA approval for the treatment of TR.
Share on Twitter Share on Facebook Share on Linkedin

CMS proposes major TAVR changes, including Medicare coverage for asymptomatic patients

Share on Twitter Share on Facebook Share on Linkedin
2024 has been a banner year for structural heart treatments, especially those focused on the tricuspid valve. In February, for example, Edwards Lifesciences made history when its Evoque transcatheter tricuspid valve replacement (TTVR) system became the first device of its kind to gain U.S. Food and Drug Administration (FDA) approval for treating tricuspid regurgitation (TR). Two months later, Abbott’s TriClip transcatheter edge-to-edge repair (TEER) system also gained FDA approval for the treatment of TR.
After months of consideration, CMS has proposed sweeping changes to its TAVR coverage policies. The agency is accepting public comments until July 15.
READ MORE >

In Case You Missed It

Medtronic recalls thousands of surgical devices due to contamination risk

This Class II recall includes more than 18,000 cannulae used during cardiac surgery.

READ MORE >
warning safety alert recall healthcare issue
Share on Twitter Share on Facebook Share on Linkedin

Medtronic recalls thousands of surgical devices due to contamination risk

Share on Twitter Share on Facebook Share on Linkedin
warning safety alert recall healthcare issue
This Class II recall includes more than 18,000 cannulae used during cardiac surgery.
READ MORE >

FDA warns public about Johnson & Johnson heart pump controllers after patient death

The FDA has identified another safety concern with Johnson & Johnson MedTech's Automated Impella Controllers. This comes after the devices were linked to five separate recalls in 2025. 

READ MORE >
The FDA has identified another safety concern with Johnson & Johnson MedTech's Automated Impella Controllers. This comes after the devices were linked to five separate recalls in 2025.
Share on Twitter Share on Facebook Share on Linkedin

FDA warns public about Johnson & Johnson heart pump controllers after patient death

Share on Twitter Share on Facebook Share on Linkedin
The FDA has identified another safety concern with Johnson & Johnson MedTech's Automated Impella Controllers. This comes after the devices were linked to five separate recalls in 2025.
The FDA has identified another safety concern with Johnson & Johnson MedTech's Automated Impella Controllers. This comes after the devices were linked to five separate recalls in 2025. 
READ MORE >

Advocacy group wants TAVR changes, urging Trump admin to ‘stop getting in between patients and their doctors’

The Alliance for Aging Research wants CMS to go through with policy changes that could make many more patients eligible for TAVR. The agency is currently considering the changes, and a final decision is expected in June. 

READ MORE >
2024 has been a banner year for structural heart treatments, especially those focused on the tricuspid valve. In February, for example, Edwards Lifesciences made history when its Evoque transcatheter tricuspid valve replacement (TTVR) system became the first device of its kind to gain U.S. Food and Drug Administration (FDA) approval for treating tricuspid regurgitation (TR). Two months later, Abbott’s TriClip transcatheter edge-to-edge repair (TEER) system also gained FDA approval for the treatment of TR.
Share on Twitter Share on Facebook Share on Linkedin

Advocacy group wants TAVR changes, urging Trump admin to ‘stop getting in between patients and their doctors’

Share on Twitter Share on Facebook Share on Linkedin
2024 has been a banner year for structural heart treatments, especially those focused on the tricuspid valve. In February, for example, Edwards Lifesciences made history when its Evoque transcatheter tricuspid valve replacement (TTVR) system became the first device of its kind to gain U.S. Food and Drug Administration (FDA) approval for treating tricuspid regurgitation (TR). Two months later, Abbott’s TriClip transcatheter edge-to-edge repair (TEER) system also gained FDA approval for the treatment of TR.
The Alliance for Aging Research wants CMS to go through with policy changes that could make many more patients eligible for TAVR. The agency is currently considering the changes, and a final decision is expected in June. 
READ MORE >

In Other News

Major private payer encouraging employees to leave willingly

The largest Medicaid-specialized managed care organization in the U.S. is offering buyout packages to most of its 60,000 or so staff workers.

READ MORE >
signature
Share on Twitter Share on Facebook Share on Linkedin

Major private payer encouraging employees to leave willingly

Share on Twitter Share on Facebook Share on Linkedin
signature
The largest Medicaid-specialized managed care organization in the U.S. is offering buyout packages to most of its 60,000 or so staff workers.
READ MORE >

In the rush for AI gold, healthcare is getting left in the dust by finance

If the economy were an inter-sector track meet in which AI adoption propels the runners, healthcare would be getting repeatedly lapped by financial services. 

READ MORE >
two runners
Share on Twitter Share on Facebook Share on Linkedin

In the rush for AI gold, healthcare is getting left in the dust by finance

Share on Twitter Share on Facebook Share on Linkedin
two runners
If the economy were an inter-sector track meet in which AI adoption propels the runners, healthcare would be getting repeatedly lapped by financial services. 
READ MORE >

Innovate Healthcare thanks our partners for supporting our newsletters.
Sponsorship has no influence on editorial content.

Interested in reaching our audiences, contact our team

*|LIST:ADDRESSLINE|*

You received this email because you signed up for newsletters from Innovate Healthcare.
Change your preferences or unsubscribe here

Contact Us  |  Unsubscribe from all  |  Privacy Policy

© Innovate Healthcare, a TriMed Media brand
Innovate Healthcare

Recent Newsletters

Early reactions to proposed TAVR changes | Cardiology still an AI leader | More than 11K bottles of blood pressure drug recalled
TV star's family awarded $13M in malpractice case | Helping patients with ‘broken hearts’ | Cardiac amyloidosis in the spotlight
CMS proposes major TAVR changes | The real impact of RVU cuts in electrophysiology | Girl’s heart valve implanted upside down
News Alert: CMS proposes major TAVR changes
Cath lab kits recalled | Looking ahead to the future of FFR-CT | Medtronic completes major acquisition
FDA sees potential in heart failure software | SCCT & SCAI take on CT-derived FFR | Predicting long-term stroke risk
Abbott recalls heart monitoring tech | Redo TAVR with balloon-expandable valves | FDA clears new clot-removing device

Pagination

    • Current page 1
    • Page 2
    • Page 3
    • Page 4
    • Page 5
    • Page 6
    • Page 7
    • Page 8
    • Page 9 …
    • Next page ››
    • Last page Last »
  • Home
  • News
  • Article Archive
  • Custom Content
  • Webinars
  • Press Releases
  • Content Studio
  • Advertising
  • Submit Press Release
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Cardiovascular Business
  • HealthExec
  • Radiology Business
 
© 2026 Innovate Healthcare | All Rights Reserved. | Terms of Use | Privacy Policy
 
Design by Adaptive Theme
Trimed Popup